Immutep (IMMP) announced that the FDA has granted Orphan Drug Designation for eftilagimod alfa for the treatment of Soft Tissue Sarcoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Advances First-in-Class LAG-3 Agonist IMP761 With Positive Phase I Progress
- Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease
- Immutep Halts Pivotal Lung Cancer Trial After Futility Review, Extends Cash Runway
- Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?
- Morning News Wrap-Up 3/13/26: Friday’s Biggest Stock Market Stories!